AbbVie presents 60 dermatology study updates at EADV
- AbbVie (NYSE:ABBV) announced 60 research abstracts, including three late-breaking presentations, for the 2026 EADV Congress.
- The data covers approved medicines SKYRIZI and RINVOQ, as well as investigational compounds lutikizumab and zumilokibart across immune-mediated skin diseases.
- AbbVie stated that the research supports its continued development of treatments for conditions including alopecia areata, atopic dermatitis, hidradenitis suppurativa, vitiligo, psoriasis and psoriatic arthritis.
AbbVie (NYSE:ABBV) announced that it will present 60 dermatology research abstracts, including three late-breaking presentations, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, covering multiple immune-mediated skin diseases.
The presentations include new clinical and real-world data across AbbVie’s dermatology portfolio, including SKYRIZI (risankizumab), RINVOQ (upadacitinib), and investigational compounds lutikizumab and zumilokibart, compared with earlier research focused on individual disease areas.
The research includes 52-week data from Phase 3 UP-AA trials evaluating upadacitinib in alopecia areata, Phase 2 APEX studies of zumilokibart in atopic dermatitis, Phase 2 studies of lutikizumab in hidradenitis suppurativa, and Phase 3 analyses of upadacitinib in non-segmental vitiligo.
AbbVie’s dermatology portfolio includes treatments and clinical programs targeting inflammatory skin conditions, with SKYRIZI and RINVOQ among its approved therapies evaluated across several dermatology indications.
The company continues research programs in immune-mediated diseases, with additional EADV presentations covering psoriasis, psoriatic arthritis, patient-reported outcomes, safety analyses and real-world treatment studies.
